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Hepatitis B remains an important health problem, with 
more than 1500 cases of acute infection occurring each 
year.’ HIV-infected adults may be at increased risk of 
exposure to hepatitis B infection, and both diseases can 
be transferred from mothers to infants. HIV-infected 
children have inadequate responses to T-cell-dependent 
vaccines.* Suboptimal responses to recombinant DNA 
hepatitis B virus vaccination were reported in persons 
with impaired humoral or cellular immunity.3 We com- 
pared hepatitis B vaccine seroresponse rates between 
HIV-infected and uninfected infants born to HIV- 
positive mothers, and further evaluated whether boosters 
with double dosage could improve immunogenicity in 
the nonresponders. 
Full-term infants born to HIV-positive mothers who 
had no hepatitis B surface antigen (HBsAg) were 
enrolled. All subjects were born at Phramongkutklao 
Hospital from January 1996 to March 1998. Written 
informed consent was obtained, and these infants had 
scheduled clinic visits at 1,2,4,6,9 and 12 months of age 
for routine health care. 
Twenty-seven infants were included in this study. 
The inclusion criteria were: (1) full-term live birth of 
HIV-positive mothers who had no HBsAg; (2) docu- 
mentation of three hepatitis B vaccinations; and (3) the 
availability of peripheral blood specimens following the 
schedules. The exclusion criteria were: (1) infants diag- 
nosed by the clinic or any laboratory as having other 
immunodeficiency diseases during follow-up; (2) infants 
receiving immunosuppressive drugs, intravenous 
immunoglobulin, or blood products; and (3) history of 
clinical hepatitis with positive HBsAg. 
Recombinant DNA hepatitis B vaccine was 
manufactured and supplied by the Thai Ministry of 
Public Health. Each dose contains 10 ug of noninfectious 
purified surface antigen. All vaccines came from the 
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same manufacturing lot. The protocol was to give 
hepatitis B vaccine concurrently with Bacille Calmette- 
Guerin (BCG) at birth, separately at 1 month, and 
concurrently with diphtheria-tetanus-pertussis (DTP) 
at 6 months of age. A reinforcement double dosage 
of hepatitis B vaccine (20 pg) was given to each non- 
responder, and serum for anti-HBs was evaluated 2-3 
months later. 
HBsAg and anti-HBs IgG were examined at l-2 
and 9 months of age using commercial enzyme immuno- 
assay (EIA) kits (Roche Diagnostic, Meylan, France) 
on serum samples at 3 months after the third dose 
of the vaccine. Infants with anti-HBs 210 IU/L were 
defined as responders, and those with anti-HBs ~10 
IU/L were considered to be nonresponders. HIV PCR 
was performed by AFRIMS using HIV-l universal 
primers as described in a previous study.4 Two or 
more positive results were considered to indicate HIV 
infection. Total CD4 count and percentage were 
evaluated twice at AFRIMS by an immunostaining 
method using the Becton Dickinson FAC Scan. 
The Student t-test was used to compare continuous 
variables between the two groups, and chi-square or 
Fisher exact test were used for categorical variables. All 
P-values reported were two-tailed. 
Among 27 infants, six (22.2%) were considered to 
be HIV infected and were assigned to the study group, 
and the remainder were HIV uninfected and assigned to 
the control group. There were no significant differences 
between HIV-infected and uninfected infants with 
respect to sex, mean birth weight and birth length. Mean 
CD4 count and percentage at l-2 months of age in the 
HIV-infected group were lower than those in the HIV- 
uninfected group (1587.8 and 2967.5 cell/mL, PcO.05; 
28.8% and 39.0%, PcO.05); however, they were within 
the normal limits for the age.5 At 9 months of age, means 
of body weight, height, CD4 count and percentage in 
the HIV-infected group were significantly lower than 
those in the HIV-uninfected group (7808.3 and 9050.0 g, 
P<O.O5; 69.0 and 72.7 cm, PcO.05; 1727.0 and 2958.1 
cell/mL, PcO.05; 23.7% and 36.6%, PcO.05). 
All vaccinations were well tolerated. None of the 
patients developed clinical hepatitis or became HBsAg 
positive at 9 months of age. The vaccine response rate of 
the HIV-infected group was 216 (33.3%), which was 
lower than that of the HIV-uninfected group (20/21, 
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Table 1. Sex, CDC Classification, CD4 studies at 9 months of age, antiretroviral therapy (ART) history and anti-HBs titer of the 6 HIV- 
infected infants. 
Case se@ CDC Classifications at 9 months of age antiretroviral therapy anti HBs (/U/L) 
at I-2mo at9mo % CD4# CD4 cow-& AZT plus start (mo) at 9 mo after revaccination 
1 M Nl Al 35 2,190 ddl 2 0 174 
2 M c2 c2 21 1,990 ddC 2 0 0 
3 M A2 A2 21 1,450 ddl 6 0 0 
4 F Al A2 18 1,910 ddC 12 0 0 
5 M Al A3 12 1,640 ddl 6 150* 
6 F Al A2 35 1,180 ddl 9 339* 
“M: male; F: female *Geometric mean antibody titer was 225.5 W/L 
*The CDC Classification includes (1) clinical categories as N, A, B and C referring to no, mild, moderate and severe signs and symptoms. 
(2) immunological categories as 1, 2, and 3 referring to no evidence of suppression, evidence of moderate and severe suppression respectively.5 
#For infants aqe from birth to 12 months, the normal value of %CD4 is 225% and CD4 count is 21500 cells/bL. 
AZT, zidovudine; ddl, didanosine; ddC, zalcitabine. 
95.2%, P<O.O05). Geometric mean antibody titers were 
225.5 and 342.0 IU/L in the HIV-infected and HIV- 
uninfected groups, respectively. 
Two of four non-immunosuppressed HIV-infected 
infants (CDC class 1) became responders in early life, 
contrasting with two moderately immunosuppressed 
infants (CDC class 2), who remained nonresponders. 
Antiretroviral combination therapy was provided as 
shown in Table 1. One of four HIV-infected non- 
responders and only one HIV-uninfected nonresponder 
seroconverted after revaccination with the double 
dosage. 
The antibody response to hepatitis B vaccine has 
been shown to be both T-cell dependent and T-cell inde- 
pendent.” The ranges of seroprotective rates in HIV- 
infected children were 25-45% after three conventional 
doses and 20-78% after double-dosage challenge.h-” 
Since one of the HIV-infected nonresponders had 
normal CD4 counts at both 1 and 9 months of age, this 
implies that the function of CD4’ lymphocytes was also 
an important factor in the patient developing protective 
antibodies. Our data suggest that it was unable to predict 
which of these HIV-infected infants was likely to 
respond to the vaccine, but those who developed 
protective antibody levels should have had normal CD4 
counts in early life. The limited impact of CDC clinical 
and immunologic class, CD4’ lymphocyte count or 
antiretroviral use on the magnitude of response was also 
shown in some studies.6-8 In contrast to the results of 
Choudhury’s study,” revaccination with HBV vaccine at 
double dosage successfully induced a protective level in 
some HIV-infected nonresponders without a correlation 
with the child’s CD4 count. Further studies are needed 
to improve the immunogenicity in these patients; for 
example, repeating the whole three-dose HBV vaccine, 
using highly active antiretroviral therapy, or using the 
vaccine containing Pre-Sl/Pre-S2 antigens.‘” We 
conclude that the antibody response to hepatitis B 
vaccination was poor in HIV-infected infants. Double- 
dosage revaccination also failed to elicit protective 
antibody levels in most cases. 
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